CENTPROPAZINE

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N2O3
Molecular Weight	368.4693
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CENTPROPAZINE

Structure Search

SMILES

CCC(=O)C1=CC=C(OCC(O)CN2CCN(CC2)C3=CC=CC=C3)C=C1

InChI

InChIKey=ZQPXSRTZFYHSFB-UHFFFAOYSA-N

InChI=1S/C22H28N2O3/c1-2-22(26)18-8-10-21(11-9-18)27-17-20(25)16-23-12-14-24(15-13-23)19-6-4-3-5-7-19/h3-11,20,25H,2,12-17H2,1H3

HIDE SMILES / InChI

Molecular Formula	C22H28N2O3
Molecular Weight	368.4693
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
serotonin receptor signaling pathway 6 Target ID: GO:0007210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21776129	Modulator 846

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:27:43 GMT 2025` Edited by `admin` on `Tue Apr 01 16:27:43 GMT 2025`
Record UNII	R5YPG9LA47
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CENTPROPAZINE

Common Name

English

1-(4-(2-HYDROXY-3-(4-PHENYLPIPERAZIN-1-YL)PROPOXY)PHENYL)PROPAN-1-ONE

Preferred Name

English

4'-(2-HYDROXY-3-(4-PHENYLPIPERAZIN-1-YL)PROPOXY)PROPIOPHENONE

Systematic Name

English

1-PROPANONE, 1-(4-(2-HYDROXY-3-(4-PHENYL-1-PIPERAZINYL)PROPOXY)PHENYL)-

Systematic Name

English

Code System Code Type Description

MANUFACTURER PRODUCT INFORMATION

CENTPROPAZINE

Created by admin on Tue Apr 01 16:27:43 GMT 2025 , Edited by admin on Tue Apr 01 16:27:43 GMT 2025

PRIMARY

CAS No. 34675-77-9; Chemical Name: Centpropazine

CAS

91315-34-3

Created by admin on Tue Apr 01 16:27:43 GMT 2025 , Edited by admin on Tue Apr 01 16:27:43 GMT 2025

PRIMARY

EPA CompTox

DTXSID00919825

Created by admin on Tue Apr 01 16:27:43 GMT 2025 , Edited by admin on Tue Apr 01 16:27:43 GMT 2025

PRIMARY

PUBCHEM

118176

Created by admin on Tue Apr 01 16:27:43 GMT 2025 , Edited by admin on Tue Apr 01 16:27:43 GMT 2025

PRIMARY

FDA UNII

R5YPG9LA47

Created by admin on Tue Apr 01 16:27:43 GMT 2025 , Edited by admin on Tue Apr 01 16:27:43 GMT 2025

PRIMARY

Related Record Type Details


					R5YPG9LA47

ACTIVE MOIETY

Comments:

Single oral doses of 10 to 160 mg centpropazine, a new antidepressant (synthesized by CDRI, Lucknow, India) were administered to groups of 4-5 male volunteers, each dose being interspersed with placebo in a double blind, non-crossover study by random distribution. The drug was well tolerated. Drowsiness, heaviness, weakness and/or headache were reported only at doses of 120 mg and above. No adverse effect was noted in various laboratory tests, ECG or vital parameters.

Amount:


					R5YPG9LA47

ACTIVE MOIETY

Comments:

Centpropazine is a new antidepressant with minimal anticholinergic effects in preclinical animal models. In this study centpropazine has been compared with imipramine in a double blind randomized multicentric study. A total of 159 patients of major depressive disorder (79 in centpropazine group and 80 in imipramine group) from four centres were included in this trial. Each patient was randomised to receive either centpropazine in a dose of 40 to 120 mg per day or imipramine in a dose of 50 to 150 mg per day for a period of six weeks. The antidepressant efficacy of centpropazine was comparable to imipramine but anticholinergic side effects were four times less than imipramine.

Amount: